TARS — Tarsus Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- $1.20bn
- $1.00bn
- $17.45m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -4.67 | -26.8 | -13.8 | -62.1 | -136 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 0.475 | 4.12 | 15.9 | 13.7 | 17.2 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.485 | 1.46 | 1.37 | -0.951 | 0.306 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -3.67 | -21.1 | 3.75 | -49 | -117 |
Capital Expenditures | -0.175 | -0.456 | -0.586 | -0.506 | -5.5 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | — | — | — | -144 | 146 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.175 | -0.456 | -0.586 | -145 | 141 |
Financing Cash Flow Items | — | 91.7 | -0.303 | -0.95 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 59.4 | 132 | 0.021 | 94 | 130 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 55.6 | 110 | 3.18 | -99.7 | 153 |